This topic contains a solution. Click here to go to the answer

Author Question: Adverse selection in competitive insurance markets harms a. high-risk individuals. b. low risk ... (Read 81 times)

LCritchfi

  • Hero Member
  • *****
  • Posts: 519
Adverse selection in competitive insurance markets harms
 a. high-risk individuals.
  b. low risk individuals.
  c. owners of competitive insurance companies.
  d. everyone.

Question 2

Adverse selection arises in insurance markets because
 a. insurance buyers have more information than insurance sellers.
  b. insurance sellers have more information than insurance buyers.
  c. individuals can select which insurance company to patronize.
  d. insurance companies can exercise too much control over whom they insure.



Related Topics

Need homework help now?

Ask unlimited questions for free

Ask a Question
Marked as best answer by a Subject Expert

Alyson.hiatt@yahoo.com

  • Sr. Member
  • ****
  • Posts: 354
Answer to Question 1

b

Answer to Question 2

a




LCritchfi

  • Member
  • Posts: 519
Reply 2 on: Jul 1, 2018
Wow, this really help


FergA

  • Member
  • Posts: 352
Reply 3 on: Yesterday
Thanks for the timely response, appreciate it

 

Did you know?

In 1844, Charles Goodyear obtained the first patent for a rubber condom.

Did you know?

The top five reasons that children stay home from school are as follows: colds, stomach flu (gastroenteritis), ear infection (otitis media), pink eye (conjunctivitis), and sore throat.

Did you know?

Giardia is one of the most common intestinal parasites worldwide, and infects up to 20% of the world population, mostly in poorer countries with inadequate sanitation. Infections are most common in children, though chronic Giardia is more common in adults.

Did you know?

Disorders that may affect pharmacodynamics include genetic mutations, malnutrition, thyrotoxicosis, myasthenia gravis, Parkinson's disease, and certain forms of insulin-resistant diabetes mellitus.

Did you know?

Bisphosphonates were first developed in the nineteenth century. They were first investigated for use in disorders of bone metabolism in the 1960s. They are now used clinically for the treatment of osteoporosis, Paget's disease, bone metastasis, multiple myeloma, and other conditions that feature bone fragility.

For a complete list of videos, visit our video library